Patient portal

IntReALL-BCP-2020 (ALL)

Clinical study on the treatment of children with a first relapse of B-cell acute lymphoblastic leukemia (B-ALL). 

Recruiting

Who can enter

  • Children with first relapse B-cell acute lymphoblastic leukemia (B-ALL)

  • Age: between 0 and 21 years old

Goal

The goal of this study is to improve the treatment for patients with a relapsed B-ALL and to reduce the side effects.

Background

When ALL relapses, a long treatment with chemotherapy, and for some children a stem cell transplantation, is needed again. Currently, despite this treatment, we are not able to cure all the children whose ALL relapses. 

In recent years, new medicinal products have become available that may improve treatment. These medications usually cause fewer severe side effects than chemotherapy. In this research, we are investigating whether the drugs 'inotuzumab ozogamicin' and 'blinatumomab' improve treatment.

For standard-risk patients: 

  • We are investigating whether administering inotuzumab ozogamicin in the first 4 weeks after diagnosis results in a better outcome than 4 weeks of chemotherapy. 

  • We are investigating whether treatment outcomes are better if we replace a 4 week chemotherapy cycle with blinatumomab at three points during the treatment.

For high-risk patients: 

  • We are investigating whether one cycle of chemotherapy followed by one cycle of blinatumomab results in the same outcome as two cycles of chemotherapy followed by one cycle of blinatumomab.

For patients with a relapse outside the bone marrow: 

  • We are investigating whether treatment outcomes are better if we replace one 4-week chemotherapy cycle with blinatumomab.

 

In order to participate in a study please refer to your/your child’s doctor.

Last reviewed

October 15, 2026

Study details

The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.